Eurofins Scientific (ERF) Stock Overview
Provides various analytical testing and laboratory services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ERF Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Eurofins Scientific SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €70.44 |
| 52 Week High | €74.32 |
| 52 Week Low | €54.86 |
| Beta | 0.84 |
| 1 Month Change | 0.23% |
| 3 Month Change | 14.91% |
| 1 Year Change | 4.60% |
| 3 Year Change | 31.03% |
| 5 Year Change | -40.80% |
| Change since IPO | 29,500.37% |
Recent News & Updates
Narrative Update • Aug 04
ERF: Acquisition Plans And Buybacks Will Support Balanced Long Term Outlook
The analyst price target for Eurofins Scientific has moved to €68.50 from €67.50, as analysts cite updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E to support their view. What's in the News Eurofins Scientific agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America, with closing targeted for the fourth quarter of 2026 subject to customary regulatory approvals, according to recent company announcements.
Narrative Update • Jul 21
ERF: Acquisition Plans And Hantavirus Testing Will Pressure Margins And Future P/E
Analysts have increased their fair value estimate for Eurofins Scientific from €48.32 to €58.00, citing updated assumptions for revenue growth, profit margins and future P/E that support a higher long-term price target framework. What's in the News Eurofins Scientific agreed to acquire Element Materials Technology's Life Sciences Testing Services business in North America, with closing subject to customary conditions and regulatory approvals and targeted for Q4 2026, according to recent transaction announcements.Recent updates
Narrative Update • Aug 04
ERF: Acquisition Plans And Buybacks Will Support Balanced Long Term Outlook
The analyst price target for Eurofins Scientific has moved to €68.50 from €67.50, as analysts cite updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E to support their view. What's in the News Eurofins Scientific agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America, with closing targeted for the fourth quarter of 2026 subject to customary regulatory approvals, according to recent company announcements.Narrative Update • Jul 21
ERF: Acquisition Plans And Hantavirus Testing Will Pressure Margins And Future P/E
Analysts have increased their fair value estimate for Eurofins Scientific from €48.32 to €58.00, citing updated assumptions for revenue growth, profit margins and future P/E that support a higher long-term price target framework. What's in the News Eurofins Scientific agreed to acquire Element Materials Technology's Life Sciences Testing Services business in North America, with closing subject to customary conditions and regulatory approvals and targeted for Q4 2026, according to recent transaction announcements.Narrative Update • Jun 12
ERF: Hantavirus Testing Uncertainty Will Challenge Margin Outlook And P/E Re Rating
Analysts have made a small upward adjustment to Eurofins Scientific's fair value estimate to €48.32, reflecting updated views on the discount rate, revenue growth, profit margin assumptions, and a higher future P/E multiple. What's in the News Eurofins companies are monitoring a hantavirus outbreak linked to a cruise ship, with 11 reported cases and 3 deaths associated with the Andes strain as of 12 May.
Narrative Update • May 29
ERF: Expanded Hantavirus Testing Network Will Support Re Rating Potential
Analysts have trimmed their price target on Eurofins Scientific from €93 to €86, reflecting updated assumptions around fair value, revenue growth, profit margins, and future P/E multiples. What's in the News Eurofins companies are monitoring a hantavirus outbreak linked to a cruise ship, with 11 reported cases and 3 deaths associated with the Andes strain, and are positioning existing testing capabilities to address potential demand across multiple countries (Key Developments).Narrative Update • May 12
ERF: Buyback Plans And Updated Assumptions Will Support Future Upside Potential
Analysts have nudged their price target for Eurofins Scientific slightly lower from about €71.71 to roughly €70.74, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News A board meeting is scheduled for April 23, 2026, to consider shares to be purchased under a new buyback programme, which could affect the share count and capital allocation plans (Key Developments).Narrative Update • Apr 21
ERF: Expanded Testing Capabilities And Higher Dividend Intend To Support Re Rating
Analysts have lifted their price target on Eurofins Scientific by €10.20, citing updated assumptions around revenue growth, profit margins, and the forward P/E multiple. Analyst Commentary Recent research points to a more constructive stance on Eurofins Scientific, with bullish analysts adjusting their assumptions around revenue growth, profitability, and valuation multiples to support a higher price target.Narrative Update • Apr 06
ERF: Revised Assumptions And Expanded Capabilities Will Support Future Re Rating Potential
Analysts have increased their price target on Eurofins Scientific by €10.20, citing updated assumptions about discount rates, revenue growth, profit margins and future P/E as the key drivers of the change. Analyst Commentary Bullish analysts are reacting positively to the revised price target on Eurofins Scientific, pointing to updated assumptions around discount rates, revenue growth, profit margins and future P/E as key inputs behind the higher valuation range.Narrative Update • Mar 23
ERF: Expanded Testing Capacity And Buybacks Will Support Re Rating Potential
Analysts have raised their price target for Eurofins Scientific by €10.20 to reflect updated views on its earnings outlook and valuation. Analyst Commentary Recent research points to a more constructive stance on Eurofins Scientific, with bullish analysts adjusting their models and valuation assumptions to support a higher price target.Narrative Update • Mar 08
ERF: Expanded Testing Capacity And Higher Expected Margins Will Support Re Rating Potential
Analysts have lifted their price target for Eurofins Scientific to €93, citing updated assumptions on fair value, discount rate, revenue growth, profit margins and future P/E, in line with recent Street research that includes a €10.20 target increase highlighted by Citi. Analyst Commentary Bullish analysts are framing the higher €93 price target as a reset of fair value that better reflects their updated assumptions on discount rate, revenue trajectory, profitability and future P/E multiples.Narrative Update • Feb 22
ERF: Updated Earnings Assumptions And Testing Expansion Will Shape Future Returns
Analysts have lifted their fair value estimate for Eurofins Scientific from about €66.34 to €71.71. This reflects updated assumptions on discount rates, revenue growth, profit margins and future P/E after recent price target increases, such as the €10.20 raise cited in Street research.Narrative Update • Feb 08
ERF: Higher Discount Rate Will Pressure Execution And P/E Re Rating
Analysts have lifted their price target on Eurofins Scientific by €10.20, reflecting updated views on its projected discount rate, revenue growth, profit margin, and future P/E profile. Analyst Commentary Even with a higher price target of €10.20, some bearish analysts are still striking a cautious tone on Eurofins Scientific.Analysis Article • Feb 07
The Strong Earnings Posted By Eurofins Scientific (EPA:ERF) Are A Good Indication Of The Strength Of The Business
Investors were underwhelmed by the solid earnings posted by Eurofins Scientific SE ( EPA:ERF ) recently. Our analysis...Narrative Update • Jan 25
ERF: Expanded Testing Capacity Will Support Future Earnings Re-Rating Potential
Analysts have lifted their fair value estimate for Eurofins Scientific to €88.00 from €84.93, aligning this with a higher Street price target of €60, as they factor in updated assumptions on revenue growth, profit margin, and future P/E multiples. Analyst Commentary Bullish analysts are pointing to the refreshed fair value estimate of €88.00 and the higher Street price target of €60 as signs that expectations around Eurofins Scientific's execution and earnings potential have been recalibrated upward.Analysis Article • Jan 14
Investors Appear Satisfied With Eurofins Scientific SE's (EPA:ERF) Prospects As Shares Rocket 27%
Eurofins Scientific SE ( EPA:ERF ) shareholders would be excited to see that the share price has had a great month...Narrative Update • Jan 10
ERF: Mixed Price Views And New Testing Capacity Will Shape Future Performance
Analysts have nudged their price target higher to about €66 from about €64, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that align with recent mixed Street target moves between €60 and €63.50. Analyst Commentary Recent Street updates on Eurofins Scientific offer a mixed picture, with one price target moving higher and another moving lower, but both clustered in the low €60s.Narrative Update • Dec 26
ERF: Narrowing Upside Will Expose Execution Risks In Testing Network
Analysts have increased our fair value estimate for Eurofins Scientific to EUR 48 from EUR 46, reflecting slightly stronger expectations for revenue growth and profitability that more than offset a modestly higher discount rate. Analyst Commentary Recent Street commentary on Eurofins Scientific reflects a mixed but increasingly cautious tone, with some upward revisions to price targets offset by reduced upside potential and more conservative growth assumptions.Narrative Update • Dec 12
ERF: Rising Testing Demand Will Support Gradual Margin Expansion Ahead
Analysts have modestly revised their fair value estimate for Eurofins Scientific lower to approximately EUR 85 from about EUR 89, reflecting a slightly higher perceived risk profile and marginally softer expectations for long term growth and profitability, despite mixed recent price target adjustments on the Street. Analyst Commentary Bullish analysts see the recent upward adjustment in price targets as a sign that execution risks are becoming more manageable, even if sentiment across the Street remains mixed.Analysis Article • Nov 23
Is Eurofins Scientific SE (EPA:ERF) Trading At A 36% Discount?
Key Insights The projected fair value for Eurofins Scientific is €90.96 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Nov 02
These 4 Measures Indicate That Eurofins Scientific (EPA:ERF) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Narrative • Feb 02
Digital Initiatives And Lab Expansion Set To Transform Operations By 2027
Long-term investments in CapEx and digitalization are expected to enhance future revenue, improve net margins, and boost earnings.Shareholder Returns
| ERF | FR Life Sciences | FR Market | |
|---|---|---|---|
| 7D | 0.6% | 0.5% | -1.1% |
| 1Y | 4.6% | 2.2% | 4.4% |
Return vs Industry: ERF exceeded the French Life Sciences industry which returned 2.2% over the past year.
Return vs Market: ERF matched the French Market which returned 4.4% over the past year.
Price Volatility
| ERF volatility | |
|---|---|
| ERF Average Weekly Movement | 3.4% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 10.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ERF has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ERF's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 65,000 | Gilles Martin | www.eurofins.com |
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services.
Eurofins Scientific SE Fundamentals Summary
| ERF fundamental statistics | |
|---|---|
| Market cap | €12.23b |
| Earnings (TTM) | €469.90m |
| Revenue (TTM) | €7.39b |
26.0x
P/E Ratio1.7x
P/S RatioIs ERF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERF income statement (TTM) | |
|---|---|
| Revenue | €7.39b |
| Cost of Revenue | €5.68b |
| Gross Profit | €1.71b |
| Other Expenses | €1.24b |
| Earnings | €469.90m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.71 |
| Gross Margin | 23.13% |
| Net Profit Margin | 6.36% |
| Debt/Equity Ratio | 87.3% |
How did ERF perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield27%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/17 16:53 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eurofins Scientific SE is covered by 31 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Rosenthal | Barclays |
| James Rowland Clark | Barclays |
| Carl Raynsford | Berenberg |